Reselute develops targeted antimicrobial therapies for orthopedic implant-related infections, utilizing advanced biomaterials and drug delivery systems derived from extensive academic research. Their solutions aim to accelerate recovery times and enhance patient outcomes by effectively addressing the persistent challenge of post-surgical infections.
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Orthopedic implant-related infections pose a significant challenge in post-surgical care, leading to prolonged recovery times and adverse patient outcomes. Current treatment methods often struggle to effectively eradicate these infections, necessitating extended antibiotic regimens and, in some cases, revision surgeries.
Solution
Reselute is developing targeted antimicrobial therapies designed to address orthopedic implant-related infections. Their approach leverages advanced biomaterials and drug delivery systems to provide localized and sustained antimicrobial action directly at the site of infection. This targeted delivery aims to improve treatment efficacy, accelerate recovery, and minimize systemic side effects associated with traditional antibiotic administration. By focusing on innovative technologies derived from extensive academic research, Reselute seeks to enhance patient outcomes and reduce the burden of post-surgical infections.
Target Audience
The primary target audience includes orthopedic surgeons, hospitals, and patients undergoing orthopedic implant procedures who are at risk of or have developed implant-related infections.
Features
- Advanced biomaterials engineered for biocompatibility and controlled drug release.
- Targeted drug delivery systems designed to concentrate antimicrobial agents at the infection site.
- Antimicrobial therapies specifically formulated to combat common pathogens associated with orthopedic implant infections.